Symbols / FBIOP Stock $14.36 -0.42% Fortress Biotech, Inc.

Healthcare • Biotechnology • United States • NCM
FBIOP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Lindsay Allan Rosenwald M.D.
Exch · Country NCM · United States
Market Cap 77.21M
Enterprise Value 464.51M
Income -1.88M
Sales 63.26M
FCF (ttm) -47.29M
Book/sh 1.59
Cash/sh 2.46
Employees 78
Insider 10d —
IPO Nov 14, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout —
P/E —
Forward P/E —
PEG —
P/S —
P/B 9.03
P/C —
EV/EBITDA -7.08
EV/Sales 7.34
Quick Ratio 2.20
Current Ratio 2.49
Debt/Eq 108.09
LT Debt/Eq —
EPS (ttm) -0.86
EPS next Y —
EPS Growth —
Revenue Growth 6.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA -26.62%
ROE -108.74%
ROIC —
Gross Margin 48.11%
Oper. Margin -29.78%
Profit Margin 10.77%
Shs Outstand 56.68M
Shs Float 22.15M
Insider Own 0.00%
Instit Own 0.00%
Short Float —
Short Ratio 0.08
Short Interest 298.00
52W High 14.64
vs 52W High -1.91%
52W Low 5.60
vs 52W Low 156.43%
Beta 1.45
Impl. Vol. —
Rel Volume 0.07
Avg Volume 18.06K
Volume 1.33K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $14.42
Price $14.36
Change -0.42%
About

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$14.36
Latest analyst target
3. DCF / Fair value
$-15.02
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.36
Low
—
High
—
Mean
—
News
RSS: Latest FBIOP news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-07-11 ROSENWALD LINDSAY A Chief Executive Officer — 5,000 $7.48 $37,418
2024-07-10 JIN DAVID Chief Financial Officer — 500 $7.50 $3,750
2024-07-09 ROSENWALD LINDSAY A Chief Executive Officer — 5,000 $7.39 $36,971
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
63.26
+9.69%
57.67
-31.76%
84.51
+11.58%
75.74
Operating Revenue
61.24
+8.05%
56.67
-12.80%
64.99
-11.05%
73.07
Cost Of Revenue
20.92
+0.22%
20.88
-8.80%
22.89
-25.61%
30.77
Reconciled Cost Of Revenue
20.52
+3.44%
19.84
-3.99%
20.66
-32.86%
30.77
Gross Profit
42.34
+15.06%
36.80
-40.29%
61.62
+37.03%
44.97
Operating Expense
112.56
-23.97%
148.04
-26.28%
200.82
-19.20%
248.53
Research And Development
11.90
-79.08%
56.88
-46.37%
106.07
-21.36%
134.88
Selling General And Administration
96.40
+9.88%
87.73
-3.57%
90.98
-19.95%
113.66
Other Operating Expenses
—
—
—
-1.30
Total Expenses
133.48
-20.98%
168.91
-24.49%
223.71
-19.90%
279.31
Operating Income
-70.22
+36.87%
-111.24
+20.09%
-139.20
+31.62%
-203.56
Total Operating Income As Reported
-70.22
+36.38%
-110.38
+22.46%
-142.34
+30.08%
-203.56
EBITDA
-20.16
+80.70%
-104.49
+23.01%
-135.72
+29.93%
-193.69
Normalized EBITDA
-46.89
+55.22%
-104.71
+23.57%
-137.00
+29.68%
-194.82
Reconciled Depreciation
4.66
+4.41%
4.46
-25.56%
6.00
-35.88%
9.35
EBIT
-24.83
+77.21%
-108.95
+23.12%
-141.72
+30.20%
-203.05
Total Unusual Items
26.73
+11886.10%
0.22
-82.59%
1.28
+13.46%
1.13
Total Unusual Items Excluding Goodwill
26.73
+11886.10%
0.22
-82.59%
1.28
+13.46%
1.13
Special Income Charges
27.13
+3050.64%
0.86
+127.39%
-3.14
0.00
Other Special Charges
—
-4.55
—
—
Impairment Of Capital Assets
0.00
-100.00%
3.69
+17.47%
3.14
—
Write Off
—
3.69
+17.47%
3.14
—
Net Income
6.82
+114.82%
-46.00
+24.14%
-60.64
+29.96%
-86.58
Pretax Income
-33.53
+72.18%
-120.54
+21.54%
-153.63
+28.03%
-213.46
Net Non Operating Interest Income Expense
-7.62
+29.72%
-10.84
+11.92%
-12.31
-0.56%
-12.24
Interest Expense Non Operating
8.71
-24.84%
11.59
-2.74%
11.91
+14.38%
10.42
Net Interest Income
-7.62
+29.72%
-10.84
+11.92%
-12.31
-0.56%
-12.24
Interest Expense
8.71
-24.84%
11.59
-2.74%
11.91
+14.38%
10.42
Interest Income Non Operating
2.48
-7.38%
2.68
-10.66%
3.00
+114.81%
1.40
Interest Income
2.48
-7.38%
2.68
-10.66%
3.00
+114.81%
1.40
Other Income Expense
44.31
+2775.21%
1.54
+172.62%
-2.12
-190.53%
2.34
Other Non Operating Income Expenses
17.58
+1233.69%
1.32
+138.73%
-3.40
-380.08%
1.22
Gain On Sale Of Security
-0.40
+37.62%
-0.64
-114.42%
4.42
+291.85%
1.13
Gain On Sale Of Business
27.13
0.00
—
—
Tax Provision
-0.62
-298.72%
0.31
-40.12%
0.52
+16.04%
0.45
Tax Rate For Calcs
0.00
-90.95%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.51
+984.46%
0.05
-82.59%
0.27
+13.46%
0.24
Net Income Including Noncontrolling Interests
-32.91
+72.76%
-120.86
+21.60%
-154.15
+27.94%
-213.91
Net Income From Continuing Operation Net Minority Interest
6.82
+114.82%
-46.00
+24.14%
-60.64
+29.96%
-86.58
Net Income From Continuing And Discontinued Operation
6.82
+114.82%
-46.00
+24.14%
-60.64
+29.96%
-86.58
Net Income Continuous Operations
-32.91
+72.76%
-120.86
+21.60%
-154.15
+27.94%
-213.91
Minority Interests
39.73
-46.93%
74.86
-19.95%
93.52
-26.56%
127.34
Normalized Income
-19.41
+57.97%
-46.17
+25.10%
-61.65
+29.52%
-87.47
Net Income Common Stockholders
-1.88
+96.63%
-55.89
+18.61%
-68.67
+27.42%
-94.61
Diluted NI Availto Com Stockholders
-1.88
+96.63%
-55.89
+18.61%
-68.67
+27.42%
-94.61
Amortization
4.26
+24.36%
3.42
-9.11%
3.77
—
Amortization Of Intangibles Income Statement
4.26
+24.36%
3.42
-9.11%
3.77
—
Depreciation Amortization Depletion Income Statement
4.26
+24.36%
3.42
-9.11%
3.77
—
Depreciation And Amortization In Income Statement
4.26
+24.36%
3.42
-9.11%
3.77
—
Preferred Stock Dividends
8.70
-12.09%
9.89
+23.17%
8.03
+0.00%
8.03
Total Other Finance Cost
1.40
-27.95%
1.94
-42.97%
3.40
+5.43%
3.23
Line Item Trend 2023-12-31
Total Assets
167.53
Current Assets
117.02
Cash Cash Equivalents And Short Term Investments
80.93
Cash And Cash Equivalents
80.93
Receivables
15.39
Accounts Receivable
15.22
Gross Accounts Receivable
15.72
Allowance For Doubtful Accounts Receivable
-0.50
Inventory
10.21
Raw Materials
4.64
Work In Process
0.88
Finished Goods
4.99
Prepaid Assets
—
Assets Held For Sale Current
0.00
Other Current Assets
10.50
Total Non Current Assets
50.50
Net PPE
23.50
Gross PPE
32.39
Accumulated Depreciation
-8.89
Properties
0.00
Buildings And Improvements
0.58
Machinery Furniture Equipment
1.61
Construction In Progress
0.03
Other Properties
16.99
Leases
13.18
Goodwill And Other Intangible Assets
20.29
Other Intangible Assets
20.29
Investments And Advances
—
Other Non Current Assets
6.72
Total Liabilities Net Minority Interest
165.94
Current Liabilities
84.91
Payables And Accrued Expenses
70.33
Payables
37.67
Accounts Payable
34.81
Other Payable
2.02
Current Accrued Expenses
32.66
Pensionand Other Post Retirement Benefit Plans Current
—
Total Tax Payable
0.84
Income Tax Payable
0.84
Current Debt And Capital Lease Obligation
5.52
Current Debt
3.00
Other Current Borrowings
3.00
Current Capital Lease Obligation
2.52
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
4.98
Total Non Current Liabilities Net Minority Interest
81.03
Long Term Debt And Capital Lease Obligation
79.14
Long Term Debt
60.86
Long Term Capital Lease Obligation
18.28
Other Non Current Liabilities
1.89
Stockholders Equity
22.54
Common Stock Equity
22.54
Capital Stock
0.02
Common Stock
0.01
Preferred Stock
0.00
Share Issued
15.09
Ordinary Shares Number
15.09
Treasury Shares Number
0.00
Additional Paid In Capital
717.40
Retained Earnings
-694.87
Minority Interest
-20.96
Total Equity Gross Minority Interest
1.59
Total Capitalization
83.40
Working Capital
32.11
Invested Capital
86.40
Total Debt
84.66
Net Debt
—
Capital Lease Obligations
20.80
Net Tangible Assets
2.26
Tangible Book Value
2.25
Available For Sale Securities
—
Current Provisions
4.08
Duefrom Related Parties Current
0.17
Interest Payable
0.00
Inventories Adjustments Allowances
-0.30
Investmentin Financial Assets
—
Line Of Credit
0.00
Preferred Shares Number
3.43
Preferred Stock Equity
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-65.78
+17.97%
-80.19
+37.46%
-128.22
+28.53%
-179.40
Cash Flow From Continuing Operating Activities
-65.78
+17.97%
-80.19
+37.46%
-128.22
+28.53%
-179.40
Net Income From Continuing Operations
-32.91
+72.76%
-120.86
+21.60%
-154.15
+27.94%
-213.91
Depreciation Amortization Depletion
4.66
+4.41%
4.46
-25.56%
6.00
-35.88%
9.35
Depreciation
0.40
-61.25%
1.04
-53.36%
2.23
-56.07%
5.08
Amortization Cash Flow
4.26
+24.36%
3.42
-9.11%
3.77
-11.92%
4.28
Depreciation And Amortization
4.66
+4.41%
4.46
-25.56%
6.00
-35.88%
9.35
Amortization Of Intangibles
4.26
+24.36%
3.42
-9.11%
3.77
-11.92%
4.28
Other Non Cash Items
0.85
-81.25%
4.53
-58.13%
10.81
+210.93%
3.48
Stock Based Compensation
28.74
-11.89%
32.62
+91.55%
17.03
-25.92%
22.99
Asset Impairment Charge
-0.21
-105.01%
4.21
+17.61%
3.58
+1159.86%
0.28
Operating Gains Losses
-26.73
-999.06%
2.97
+187.80%
1.03
+218.19%
-0.87
Gain Loss On Investment Securities
0.40
-18.28%
0.49
+111.01%
-4.42
-291.85%
-1.13
Unrealized Gain Loss On Investment Securities
-15.07
0.00
—
0.00
Gain Loss On Sale Of PPE
0.00
-100.00%
0.03
+101.98%
-1.47
-674.90%
0.26
Change In Working Capital
-25.10
-208.80%
-8.13
+35.08%
-12.52
-1650.91%
-0.71
Change In Receivables
-19.33
-532.30%
4.47
-64.29%
12.52
+358.72%
-4.84
Changes In Account Receivables
-19.34
-532.20%
4.47
-64.35%
12.55
+333.29%
-5.38
Change In Inventory
4.81
+213.78%
-4.22
-206.88%
3.95
+126.66%
1.74
Change In Prepaid Assets
1.55
+347.76%
-0.62
+26.42%
-0.85
+67.32%
-2.60
Change In Payables And Accrued Expense
-8.55
-35.65%
-6.30
+74.03%
-24.26
-378.03%
8.73
Change In Accrued Expense
—
—
—
—
Change In Payable
-8.55
-35.65%
-6.30
+74.03%
-24.26
-378.03%
8.73
Change In Account Payable
-7.97
-24.74%
-6.39
+73.79%
-24.38
-392.03%
8.35
Change In Other Working Capital
—
—
—
-1.88
Change In Other Current Assets
0.33
-65.91%
0.97
+219.80%
-0.81
-334.88%
0.34
Change In Other Current Liabilities
-3.90
-61.59%
-2.42
+21.48%
-3.08
-39.17%
-2.21
Investing Cash Flow
10.12
+167.47%
-15.00
-613.27%
-2.10
+90.83%
-22.93
Cash Flow From Continuing Investing Activities
10.12
+167.47%
-15.00
-613.27%
-2.10
+90.83%
-22.93
Net PPE Purchase And Sale
1.17
0.00
-100.00%
5.94
+329.40%
-2.59
Purchase Of PPE
—
0.00
+100.00%
-0.06
+97.68%
-2.71
Sale Of PPE
1.17
0.00
-100.00%
6.00
+4624.41%
0.13
Capital Expenditure
—
-15.00
-85.23%
-8.10
-165.07%
-3.06
Net Business Purchase And Sale
8.96
0.00
0.00
+100.00%
-20.00
Purchase Of Business
—
—
0.00
+100.00%
-20.00
Gain Loss On Sale Of Business
-27.13
0.00
-100.00%
4.13
0.00
Net Intangibles Purchase And Sale
0.00
+100.00%
-15.00
-86.68%
-8.04
-2263.24%
-0.34
Purchase Of Intangibles
0.00
+100.00%
-15.00
-86.68%
-8.04
-2263.24%
-0.34
Net Other Investing Changes
—
—
-0.01
—
Financing Cash Flow
77.44
+9.63%
70.64
+115.77%
32.74
-56.53%
75.32
Cash Flow From Continuing Financing Activities
77.44
+9.63%
70.64
+115.77%
32.74
-56.53%
75.32
Net Issuance Payments Of Debt
-5.64
+23.11%
-7.33
+81.11%
-38.79
-178.77%
49.25
Issuance Of Debt
0.00
-100.00%
43.67
+2.68%
42.53
-18.39%
52.11
Repayment Of Debt
-5.64
+88.95%
-51.00
+37.29%
-81.32
-2739.49%
-2.86
Long Term Debt Issuance
0.00
-100.00%
43.67
+200.57%
14.53
-69.16%
47.11
Long Term Debt Payments
-5.64
+88.95%
-51.00
-1.24%
-50.38
0.00
Net Long Term Debt Issuance
-5.64
+23.11%
-7.33
+79.55%
-35.85
-176.09%
47.11
Short Term Debt Issuance
—
0.00
-100.00%
28.00
+460.00%
5.00
Short Term Debt Payments
—
0.00
+100.00%
-30.95
-980.59%
-2.86
Net Short Term Debt Issuance
—
0.00
+100.00%
-2.95
-238.01%
2.14
Net Common Stock Issuance
81.68
-1.40%
82.84
+3.07%
80.38
+105.32%
39.15
Common Stock Payments
—
—
0.00
+100.00%
-1.11
Common Stock Dividend Paid
-0.66
+4.32%
-0.69
+5.71%
-0.74
+1.74%
-0.75
Cash Dividends Paid
-0.66
+85.90%
-4.71
+46.28%
-8.77
+0.14%
-8.78
Repurchase Of Capital Stock
-0.27
0.00
+100.00%
-0.40
+66.56%
-1.20
Proceeds From Stock Option Exercised
2.95
+171.48%
1.09
+59.62%
0.68
+79.21%
0.38
Net Other Financing Charges
-0.62
+50.00%
-1.25
-3.31%
-1.21
+83.02%
-7.12
Changes In Cash
21.79
+188.74%
-24.55
+74.84%
-97.59
+23.16%
-127.01
Beginning Cash Position
58.81
-29.45%
83.36
-53.93%
180.95
-41.24%
307.96
End Cash Position
80.60
+37.04%
58.81
-29.45%
83.36
-53.93%
180.95
Free Cash Flow
-65.78
+30.90%
-95.19
+30.17%
-136.32
+25.28%
-182.46
Interest Paid Supplemental Data
7.39
+3.17%
7.16
-9.89%
7.95
-15.65%
9.42
Income Tax Paid Supplemental Data
0.05
-59.17%
0.12
—
0.86
Change In Income Tax Payable
-0.58
-747.19%
0.09
-26.45%
0.12
-67.90%
0.38
Change In Interest Payable
—
—
—
—
Change In Tax Payable
-0.58
-747.19%
0.09
-26.45%
0.12
-67.90%
0.38
Common Stock Issuance
81.68
-1.40%
82.84
+3.07%
80.38
+99.65%
40.26
Issuance Of Capital Stock
81.68
-1.40%
82.84
+1.99%
81.23
+89.83%
42.79
Net Preferred Stock Issuance
-0.27
0.00
-100.00%
0.45
-81.45%
2.45
Preferred Stock Dividend Paid
0.00
+100.00%
-4.02
+50.00%
-8.03
-0.01%
-8.03
Preferred Stock Issuance
—
0.00
-100.00%
0.85
-66.29%
2.53
Preferred Stock Payments
-0.27
0.00
+100.00%
-0.40
-370.59%
-0.09
Sale Of Business
8.96
0.00
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category